Harris Matthew Scott
Known title: Chief Medical OfficerCIK: 0001787762
Harris Matthew Scott's purchase track record
Harris Matthew Scott has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/23/2023 | ALT | $42K | -0.7% | -38.9% | +9.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ALT | ▲ Buy | Grant | 2,018 | $6K | 7/31/2025 | View on chart |
| ALT | ▼ Sell | Gift | 67,787 | $0 | 3/7/2025 | View on chart |
| ALT | ▲ Buy | Option Exercise | 7,775 | $0 | 2/2/2025 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 2,708 | $18K | 2/2/2025 | View on chart |
| ALT | ▲ Buy | Option Exercise | 6,166 | $0 | 2/1/2025 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 2,109 | $14K | 2/1/2025 | View on chart |
| ALT | ▲ Buy | Grant | 1,905 | $10K | 1/31/2025 | View on chart |
| ALT | ▲ Buy | Option Exercise | 9,275 | $0 | 1/30/2025 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 3,173 | $22K | 1/30/2025 | View on chart |
| ALT | ▲ Buy | Option Exercise | 14,600 | $0 | 1/25/2025 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 4,994 | $35K | 1/25/2025 | View on chart |
| ALT | ▲ Buy | Grant | 1,486 | $8K | 7/31/2024 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 2,332 | $22K | 2/2/2024 | View on chart |
| ALT | ▲ Buy | Option Exercise | 7,775 | $0 | 2/2/2024 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 1,801 | $18K | 2/1/2024 | View on chart |
| ALT | ▲ Buy | Option Exercise | 6,166 | $0 | 2/1/2024 | View on chart |
| ALT | ▲ Buy | Grant | 3,257 | $9K | 1/31/2024 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 2,709 | $27K | 1/30/2024 | View on chart |
| ALT | ▲ Buy | Option Exercise | 9,275 | $0 | 1/30/2024 | View on chart |
| ALT | ▲ Buy | Grant | 691 | $2K | 7/31/2023 | View on chart |
| ALT | ▲ Buy | Open Market | 10,000 | $42K | 3/23/2023 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 2,364 | $36K | 2/2/2023 | View on chart |
| ALT | ▲ Buy | Option Exercise | 7,775 | $0 | 2/2/2023 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 2,183 | $30K | 2/1/2023 | View on chart |
| ALT | ▲ Buy | Option Exercise | 6,166 | $0 | 2/1/2023 | View on chart |
| ALT | ▲ Buy | Grant | 1,296 | $13K | 1/31/2023 | View on chart |
| ALT | ▲ Buy | Grant | 1,076 | $7K | 7/31/2022 | View on chart |
| ALT | ▲ Buy | Option Exercise | 30,000 | $58K | 2/28/2022 | View on chart |
| ALT | ▼ Sell | Open Market | 30,000 | $226K | 2/28/2022 | View on chart |
| ALT | ▲ Buy | Option Exercise | 6,166 | $0 | 2/1/2022 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 2,183 | $17K | 2/1/2022 | View on chart |
| ALT | ▲ Buy | Grant | 1,800 | $12K | 1/31/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Altimmune to attend Wells Fargo healthcare conference
Altimmune has been confirmed as a participant in the Wells Fargo 21st Annual Healthcare Conference. The company joins a roster of healthcare firms presenting at the event, which is a common venue for biopharma companies to engage with investors and outline pipeline progress. No new clinical, regulatory, or financial announcements accompanied the participation news, so the development is a routine scheduling item rather than a fundamental catalyst. As context, the stock has been trading well below the average analyst price target of $17.22, with its 52-week range between $2.56 and $6.44.
Altimmune to attend Wells Fargo healthcare conference. Altimmune has been confirmed as a participant in the Wells Fargo 21st Annual Healthcare Conference. The company joins a roster of healthcare firms presenting at the event, which is a common venue for biopharma companies to engage with investors and outline pipeline progress. No new clinical, regulatory, or financial announcements accompanied the participation news, so the development is a routine scheduling item rather than a fundamental catalyst. As context, the stock has been trading well below the average analyst price target of $17.22, with its 52-week range between $2.56 and $6.44.